Aclaris Therapeutics, Inc. Aktie News

Aclaris Therapeutics, Inc. - Special Call Company Participants William Roberts - Senior VP of Corporate Communications & Investor Relations Neal Walker - Co-Founder, CEO & Chairman Roland Kolbeck - Chief Scientific Officer Joseph Monahan - Founder, Chairman of the Board & Chief Scientific Officer Hugh M. Davis - President, COO & Director Jesse Hall - Chief Medical Officer Zuzana Diamant Michael...

WAYNE, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will host it's 2025 R&D Day in Midtown, New York on Tuesday, October 14, 2025 at 8:00 AM ET to discuss the Company's progress in addressing therapeuti...

- Late Breaking Abstract to Present Additional Data from Aclaris' Phase 2a Trial of ATI-2138 in Atopic Dermatitis- WAYNE, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that a late-breaking abstract on its open-label Phas...

WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in September. On Wednesday September 3, 2025, at 1:00 PM EDT, Aclaris' Chief Executive Officer ...

- Positive Clinical Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Confirm Tolerability Profile, Show Strong Efficacy Signal, and Validate ITK as Therapeutic Target - - Advanced Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) into Phase 2 Trial in Atopic Dermatitis (AD); Patient Dosing Underway - - Initiated Dosing in Phase 1a/1b Clinical Program for Anti-TSLP/IL-4R Bispecific Ant...

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of IT

- Roland Kolbeck, Ph.D. Appointed as Chief Scientific Officer - - Joe Monahan, Ph.D.

WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as of the conclusion of the 2025 Russell US Indexes annual reconst...